Article Text

Download PDFPDF

Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma
  1. Michael Bayer1,
  2. Xiaojin Wang2,
  3. Chengwei Chen2,
  4. Xiaosong Chen3,
  5. Qingchun Fu2,
  6. Jia He4,
  7. William Cao5,
  8. Craig Fredrickson6,
  9. Jessica Cannon7,
  10. Andrew Cornforth7,
  11. Gabriel Nistor7 and
  12. Robert Dillman7
  1. Aff1 NeoStem OncologyLLC Encinitas United States
  2. Aff2 Hospital 85 People's Liberation Army of China Shanghai Peoples Republic of China
  3. Aff3 grid.415869.7Shanghai Renji Hospital Shanghai Peoples Republic of China
  4. Aff4 grid.73113.370000000403691660Second Military Medical University Shanghai Peoples Republic of China
  5. Aff5 grid.485053.fCellular Biomedicine Group Palo Alto United States
  6. Aff6 grid.417388.10000000403674756California Stem Cell, Inc Irvine United States
  7. Aff7 Neostem OncologyLLC Irvine United States

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Active or chronic infections may be barriers to successful vaccines, and patients with hepatitis typically are excluded from clinical trials testing therapeutic anticancer vaccines. One concern is vaccines may exacerbate the underlying infection. Hepatocellular carcinoma (HCC) often arises in the context of viral hepatitis B (HBV) or hepatitis C (HBC), with or without cirrhosis. HCC is seldom cured by standard therapy because of undetectable micrometastatic disease that is present at diagnosis. Effective non-toxic adjunctive treatments might improve outcomes for HCC patients who are at high risk for recurrence and death despite surgical resection of their primary hepatoma. Active specific immunotherapy (ASI) with autologous dendritic cells loaded with antigens from autologous tumor stem cell lines has been associated with promising long-term survival in metastatic melanoma, but patients with HBV or HCV were ineligible. Therefore a Phase I safety trial in HCC patients with HBV and/or HIV was warranted.

Patients and methods

Patients with previously untreated HCC who were candidates for surgical resection, but not curable by resection or liver transplant were enrolled in Shanghai, China. Patients had a solitary lesion >5 cm in diameter, or 3 lesions with at least one > 3 cm, but no regional or distant metastatic disease. Patients had a good performance status, adequate blood counts and organ function. An autologous tumor cell (TC) line was established from the resected tumor. Irradiated autologous TC were incubated with autologous dendritic cells (DC) to create a patient-specific DC-TC product which was cryopreserved. Approximately eight weeks after one course of trans-arterial chemoembolization therapy (TACE), patients received three weekly subcutaneous injections of DC-TC suspended in 500 micrograms of sargramostim. Patients were monitored for toxicity for 8 weeks from the start of treatment.


HCC cell lines were successfully established within 5 weeks for 15/15 patients. Eight patients taking anti-viral medication for active HBV infection were treated (7 men, 1 woman) with ages ranging from 37 to 73 years. Each received the planned 3 injections, which were well tolerated. There were no significant changes in various parameters, including hepatic transaminases, bilirubin, prothrombin time, hepatitis B antigens, or viral DNA.


Injections of autologous DC-TC in sargramostim were not associated with a worsening of hepatitis or other toxicities in HBV + HCC patients. This shows sufficient safety to justify a Phase II efficacy trial in similar patients.


Sponsored by Cellular Biomedicine Group, Shanghai, China, and NeoStem Inc., New York, NY, USA.